Investing Profile

Jim Tananbaum

VCInvestorCEOFounder
Founder and CEO at Foresite Capital.
foresitecapital.com/people/ji...San Francisco, California
Photo of Jim Tananbaum, Investor at Foresite Capital
Your Intro Paths to Jim Tananbaum

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Networks Jim is a member of
Harvard Business School Network
418 CONNECTIONS
Massachusetts Institute of Technology Network
176 CONNECTIONS
Yale University Network
126 CONNECTIONS
Harvard Medical School Network
20 CONNECTIONS
Sierra Ventures Network
13 CONNECTIONS

Find Jim Tananbaum on

cb
Current Investing Position
Foresite Capital Investor
Investment Range
$100K - $5.0M
Sweet Spot
$1.5M
Investments On Record
31
Current Fund Size
$668M

Jim Tananbaum is on these Sector & Stage Rankings

Jim Tananbaum's Investments On Record (21)

CompanyStageDateRound SizeTotal Raised
Alumis
Series CMar 2024$260M
Series AMay 2021$70M
$330M
Co-investors: Michael Rome (Foresite Capital), Vikram Bajaj (Foresite Capital), Richard Gaster (venBio)
Genomics
Series CJan 2024$45M
Series UnknownMar 2021$30M
$84M
Co-investors: Stephen Knight (F-Prime Capital Partners)
Foresight Diagnostics
Series BApr 2023$59M
$72M
Co-investors: Vikram Bajaj (Foresite Capital), Shahram Seyedin-Noor (Civilization Ventures)
evonetix
Series BFeb 2023$24M
Series BMar 2020$30M
$66M
Co-investors: Vishal Gulati (Molten Ventures), Ameena El-Bibany (Artis Ventures (AV)), Armen Vidian
DNAnexus
Series HMar 2022$200M
Series GJun 2020$100M
Series FFeb 2019$68M
Series EJan 2018$58M
$460M
Co-investors: Krishna Yeshwant (GV (Google Ventures)), Jeff Clavier (Uncork Capital), Manu Kumar (K9 Ventures), Rob Hayes (First Round Capital), Michael Rubin (Northpond Ventures), Nat Goldhaber
ImmPACT Bio
Series BJan 2022$140M
$140M
Co-investors: Cindy Xiong (Foresite Capital), Yvonne Yamanaka (venBio), Richard Gaster (venBio)
XinThera
Series BAug 2021$50M
$50M
Co-investors: Carl Gordon (OrbiMed), Michael Rome (Foresite Capital)
Element Biosciences
Series CJun 2021$280M
$280M
Co-investors: Bryan Roberts (Venrock)

Jim Tananbaum's Experience

Co-Founder and Chief Executive Officer Theravance (THRX)Present
Co-Founder and Managing Director PVP2 & PVP3 Prospect Venture PartnersPresent
Founder and CEO Foresite Capital ManagementPresent
Partner Sierra Ventures1993 - 1997
Co-Founder and CEO GelTex (acquired by Genzyme for $1.6 B)1991 - 1992

Jim Tananbaum's Education

Harvard Business School mba
Harvard Medical School Doctor of Medicine (MD)
Massachusetts Institute of Technology Master of Science (M.S.) HST - information theory
Yale University BS BSEE, Math, computer science